Berdazimer for Molluscum Contagiosum: Dosage, Side Effects and Pharmacology

Overview:

Berdazimer topical gel, 10.3 percent, was authorized by the FDA (Food and Drug Administration) on January 5, 2024, to treat molluscum contagiosum in people one year of age and older. According to a press statement, its clearance makes the medication the first innovative treatment for this indication.

The introduction of Berdazimer topical gel is a significant development as it allows physicians to treat molluscum for the first time using a topical prescription drug in dermatology that works well and may be administered by the patient or a family member.

Drug Group: Berdazimer is classified as an antiviral medication.

Available Doses and Dosage Forms:

Topical gel: Two tubes containing 10.3 percent Berdazimer.

Tube A includes gel Berdazimer, and the hydrogel is found in Tube B.

For Patients:

What Is Molluscum Contagiosum?

Molluscum contagiosum is a prevalent and extremely transmissible viral skin infection that results in tiny, elevated pimple-like lesions on the skin. It is mostly transmitted via direct skin-to-skin contact or contact with infected things, such as toys, clothes, or towels. It is caused by a pox virus. Although it usually affects children, adults can potentially contract molluscum contagiosum (MC). Although the lesions are normally painless, picking or scratching at them may result in subsequent bacterial infections and cosmetic issues. The infection normally goes away on its own in six to twelve months, although occasionally, it might linger longer.

How Does Berdazimer Work?

Berdazimer is an antiviral drug that functions by preventing the molluscum contagiosum virus from replicating. It stops the virus from proliferating and creating new lesions, as well as upsetting the viral life cycle. Berdazimer interferes with the virus's capacity to multiply and infect new cells by targeting particular viral proteins and enzymes. Berdazimer aids in the removal of current lesions and inhibits the growth of new ones by interfering with the viral replication process.

What Is the Dosage of Berdazimer?

The following items are included in the box that contains Berdazimer:

• Hydrogel-containing tube B.

• Berdazimer gel-containing tube A.

Dosage Guidelines

Before applying, combine equal parts of the gel from tubes A and B. For a maximum of 12 weeks, apply one dose of Berdazimer every day to every MC lesion.

How Effective Is Berdazimer?

The effectiveness of 10.3 percent Berdazimer gel in treating molluscum contagiosum has been assessed in many clinical trials. Comparing Berdazimer to a placebo (vehicle) gel, a critical Phase 3 research showed statistically significant increases in the clearance of molluscum lesions. By the twelfth week of the trial, 32.5 percent of patients receiving Berdazimer had completely cleared their lesions, whereas only 19.7 percent of patients receiving a placebo had done so. Throughout the trial, Berdazimer was also demonstrated to be beneficial in lowering the number of lesions that were already present and inhibiting the growth of new lesions. Based on these findings, Berdazimer appears to be a viable therapeutic choice for molluscum contagiosum patients, providing a greater rate of lesion clearance in comparison to the disease's natural course. or placebo.

What Are the Things to Inform the Doctor Before Taking the Drug?

• Patients should disclose to their healthcare practitioner any relevant medical history or current problems before using Berdazimer.

• As Berdazimer might not be appropriate in some situations, it is important to disclose any additional skin disorders, allergies, or sensitivities.

• To avoid any possible interactions with Berdazimer, patients should also submit a detailed list of all the medications they are presently taking, including prescription, over-the-counter, and dietary supplements.

• Additionally, as the safety and effectiveness of the drug have not been completely demonstrated in these groups, women who are pregnant or nursing should speak with their doctor before using Berdazimer.

• By giving the healthcare professional this information, one may reduce the chance of any negative side effects and guarantee that Berdazimer is used appropriately.

How Is Berdazimer Administered?

On the dosage guide, evenly distribute 0.5 mL (milliliter) of gel from tubes A and B.

Replace the caps on tube A and tube B securely as soon as possible.

• Combine according to the dosage recommendations.

• Apply Berdazimer right away in a uniformly thin coating. For a maximum of 12 weeks, apply Berdazimer once daily to each MC lesion.

• Unless the hands are being treated, wash the hands after using Berdazimer.

• After applying, give Berdazimer ten minutes to dry.

• Refrain from applying Berdazimer to unaffected parts of the skin and from getting it into the eyes or other sensitive places.

• After using Berdazimer, refrain from bathing, swimming, or cleaning for one hour.

• This product is intended for topical treatment only; it is not intended for oral, intravaginal, or ophthalmic use.

What Are the Side Effects of Berdazimer?

The most frequently reported side effects (occurring in at least one percent of patients) associated with the use of Berdazimer gel include application site reactions. These reactions can manifest as various symptoms, such as:

• Pain, including burning or stinging sensations, is experienced by 18.7 percent of patients.

• Redness (erythema) in 11.7 percent of patients.

• Itching (pruritus) in 5.7 percent of patients.

• Skin peeling (exfoliation) in 5.0 percent of patients.

• Dermatitis in 4.9 percent of patients.

• Swelling in 3.5 percent of patients.

• Erosion in 1.6 percent of patients.

• Discoloration in 1.5 percent of patients.

• Blisters (vesicles) in 1.5 percent of patients.

• Irritation in 1.2 percent of patients.

• Infection in 1.1 percent of patients.

These application site reactions were the most commonly reported adverse events associated with the use of Berdazimer gel for the treatment of molluscum contagiosum.

Dietary Considerations:

• Berdazimer gel, 10.3 percent, is not known to be related to any particular dietary needs or restrictions.

• Berdazimer is a topical drug used topically; it is not meant to be swallowed or taken internally.

• Patients should generally follow a healthy, balanced diet to promote both the body's natural healing processes and general skin health.

• Nevertheless, no particular dietary changes or supplements have been demonstrated to work in concert with Berdazimer or to increase its efficacy.

Missed Dose:

• Patients should administer their Berdazimer dosage as soon as they recall if they forget to do so at the appointed time.

• The patient should, however, forego the missed dosage and stick to the usual dosing plan if the next scheduled dose is almost here.

• To make up for a missing dosage, patients should not apply twice as much as this might raise the chance of unwanted effects.

• To get the intended therapeutic result, Berdazimer must continue to be used consistently every day.

Overdose:

• Since Berdazimer is a topical drug and not meant to be used orally, there is not much information on what happens if one overdoses on it.

• Patients should seek advice from the poison control center or their healthcare physician right away if they accidentally consume or apply too much Berdazimer.

• Increased skin irritation, nausea, and other negative effects are possible overdose symptoms; nevertheless, the precise clinical outcomes of Berdazimer overdose are not well-established.

• Patients should avoid any purposeful or inadvertent drug abuse by closely adhering to the recommended dose guidelines.

Storage:

• Before Berdazimer is given to the patient, keep it refrigerated between two degrees Celsius and eight degrees Celsius (36 degrees Fahrenheit and 46 degrees Fahrenheit). In the designated area on the carton, write the "discard after" date.

• After Dispensing: Keep Berdazimer in a dry place at room temperature, ideally between 20 and 25 degrees Celsius (68 and 77 degrees Fahrenheit).

• The product should not be frozen and should be stored away from open flames because it includes alcohol.

• Once removed from the fridge, discard after 60 days.

For Doctors

Indication:

• For the topical treatment of molluscum contagiosum in patients, Berdazimer gel, of 10.3 percent is recommended.

• Molluscum contagiosum is a prevalent and extremely transmissible viral skin infection that results in tiny, elevated pimple-like lesions on the skin.

• Patients with molluscum contagiosum who are adults or pediatricians may use Berdazimer.

Dose:

• Applying a thin coating of 10.3 percent Berdazimer gel to the afflicted regions once a day is the suggested dosage.

• Until the gel is completely absorbed, patients should gently rub it into their skin.

• It usually takes a few weeks to months for the lesions to disappear, thus the therapy should be continued until then.

Dosing Considerations:

• Berdazimer should not be consumed or applied to the face or mucous membranes; it is only meant for topical (skin) usage.

• After administering the treatment, patients should wash their hands to prevent getting the gel in their mouths, noses, or eyes.

• Patients who are pregnant or nursing should speak with their healthcare professional before using Berdazimer since the safety and effectiveness of this medicine have not been completely demonstrated in these populations.

• Patients should talk to their doctor about whether they are good candidates for Berdazimer therapy if they have specific allergies or skin issues.

• Applying Berdazimer consistently every day is crucial to getting the intended therapeutic result and curing the molluscum contagiosum lesions.

What Are the Pharmacological Aspects of Berdazimer?

Pharmacodynamics:

The pharmacodynamics of Berdazimer are unknown.

Mechanism of Action:

1. Berdazimer works by preventing the production of viral DNA (deoxyribonucleic acid) and interfering with the viral life cycle.

2. Viral enzymes necessary for the molluscum contagiosum virus to replicate, such as viral DNA (deoxyribonucleic acid) polymerase, are targeted by Berdazimer and bound to.

3. Berdazimer clears the molluscum lesions by blocking these viral enzymes, which stops the virus from effectively reproducing and infecting new host cells.

4. Berdazimer's specific action method minimizes the negative effects on healthy host cells while effectively targeting the virus.

Pharmacokinetics:

1. 10.3 percent topical gel formulation of Berdazimer is intended for skin application.

2. A small quantity of the active component, Berdazimer sodium, is absorbed into the systemic circulation when administered topically.

3. Berdazimer typically has a modest systemic exposure and causes little body accumulation even after regular administrations.

4. This absorbed Berdazimer has a terminal half-life of around eight hours and is excreted mostly through the urine.

5. Berdazimer's pharmacokinetic profile suggests a good safety profile, with little systemic exposure and quick bodily excretion.

Toxicity:

• Berdazimer's toxicity profile has been thoroughly assessed in preclinical and clinical research.

• Berdazimer, topically applied to animals, was shown to have little chance of causing systemic harm.

• Even at dosages far greater than the approved human dose, topical administration of Berdazimer did not have any appreciable deleterious effects on systemic parameters or essential organs.

• Localized skin rashes were the main harmful effect of Berdazimer, although they were usually minor and temporary.

• When used topically to treat molluscum contagiosum, Berdazimer appears to have a good safety profile, according to the toxicity data overall.

Clinical Studies:

Berdazimer's toxicity profile has been thoroughly assessed in preclinical and clinical research.

• When administered topically to animals, Benazimer has been demonstrated to have minimal potential to cause systemic damage.

• The percentage of participants who achieved full clearance (total MC lesion count of 0) at week 12 was the main efficacy objective.

Efficacy was demonstrated in trials 1 and 2:

1. In trial 1, the full clearance rate at week 12 was 32.4 percent for Berdazimer versus 19.7 percent for vehicles, with a treatment difference of 12.8 percent.

2. In trial 2, there was a 9.2 percent treatment difference in the total clearance rate at week 12 between Berdazimer and the vehicle, at 30.0 percent vs. 20.3 percent. In both trials 1 and 2, the important secondary objective of the full clearance rate at week 8 was also statistically significant, supporting Berdazimer above the vehicle.

3. In trial 3, there was a non-significant treatment difference in the full clearance rates at week 12 (26 percent for Berdazimer versus 22 percent for the vehicle).

In conclusion, two out of the three studies showed that Berdazimer was effective, with statistically significant increases in the rates of full eradication of molluscum contagiosum lesions when compared to vehicle control.

What Are the Contraindications of Berdazimer?

None.

Warnings and Precautions:

Application Site Responses

In individuals treated with Berdazimer, application site responses such as allergic contact dermatitis have happened. If experiencing discomfort, pruritus, swelling, or erythema at the application site for more than 24 hours, one may have allergic contact dermatitis. In the event of allergic contact dermatitis, stop using Berdazimer and start the proper treatment.

What Are the Drug Interactions of Berdazimer?

There are no known severe, major, moderate, or mild medication interactions with Berdazimer topical. However, it is important to note that with time, new interactions may be found.

Medication reactions might differ from person to person.

Specific Considerations:

• Pregnancy: Data on the use of Berdazimer in pregnancy are not yet available to assess the drug's potential to cause serious birth abnormalities, miscarriage, or other unfavorable consequences for either the mother or the fetus. If pregnant, breastfeeding, or planning to become pregnant, discuss the use of Berdazimer with the healthcare provider.

• Pediatrics: For the topical treatment of MC, Berdazimer has been proven safe and efficacious in children patients one year of age and older.

• Geriatrics: The number of patients 65 years of age and older in clinical investigations with Berdazimer was insufficient to ascertain if their responses differed from those of younger adult subjects.